<Disease><Name>TYROSINEMIA III</Name><Synonym>4-HYDROXYPHENYLPYRUVATE DIOXYGENASE DEFICIENCY</Synonym><OMIM><Number>276710</Number><URL>http://omim.org/entry/276710</URL></OMIM><Orphanet><Number>69723</Number><URL>http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&amp;Expert=69723</URL></Orphanet><Protein><Number>4-hydroxyphenylpyruvate dioxygenase</Number><URL>http://www.uniprot.org/uniprot/P32754</URL></Protein><ExPASy><Number>1.13.11.27</Number><URL>http://enzyme.expasy.org/EC/1.13.11.27</URL></ExPASy><Gene>12q24.31</Gene><ICD>E70.2</ICD><Summary>rare (&lt;1:1000000);autosomal recessive ;Mutations in the 4-hydroxyphenylpyruvic acid dioxygenase gene (HPD) are responsible for tyrosinemia type III and hawkinsinuria [Tomoeda K et al. 2000]</Summary><Symptoms><symtomp><id>2074</id><symptom>Amino acids, plasma</symptom><category>LABORATORY FINDINGS</category></symtomp><symtomp><id>1942</id><symptom>ataxia</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2226</id><symptom>cerebral atrophy</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>3709</id><symptom>epilepsy</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>3826</id><symptom>intellectual disability/intellectual developmental disorder</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1953</id><symptom>lethargy, drowsiness, apathy</symptom><category>NERVOUS SYSTEM | NERVOUS SYSTEM</category></symtomp><symtomp><id>2424</id><symptom>mental retardation</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2213</id><symptom>MRI, brain, abnormalities [-]</symptom><category>LABORATORY FINDINGS | NERVOUS SYSTEM</category></symtomp><symtomp><id>2505</id><symptom>onset, infancy / infancy</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2504</id><symptom>onset, neonatal / neonatal</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2089</id><symptom>Organic acids, urine</symptom><category>LABORATORY FINDINGS</category></symtomp><symtomp><id>1943</id><symptom>seizures</symptom><category>NERVOUS SYSTEM | NERVOUS SYSTEM</category></symtomp></Symptoms><Metabolites><metabolite><id>1584</id><name>4-Hydroxyphenyllactic acid</name><specimen>urine</specimen><value>increased</value><min>1.50</min><max>3.90</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite><metabolite><id>1656</id><name>L-Tyrosine</name><specimen>urine</specimen><value>increased</value><min>4.10</min><max>23.50</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite><metabolite><id>1676</id><name>4-Hydroxyphenylacetic acid</name><specimen>urine</specimen><value>increased</value><min>1.40</min><max>14.60</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite><metabolite><id>1731</id><name>4-Hydroxyphenylpyruvic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>45.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment>?</comment></metabolite><metabolite><id>1795</id><name>4-Hydroxyphenylacetic acid</name><specimen>urine</specimen><value>increased</value><min>36.00</min><max>69.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment /></metabolite><metabolite><id>1796</id><name>4-Hydroxyphenyllactic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>470.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment>?</comment></metabolite><metabolite><id>1969</id><name>L-Tyrosine</name><specimen>plasma</specimen><value>increased</value><min>34.00</min><max>112.00</max><unit>&#956;mol/l</unit><age>Adulthood</age><method>HPLC</method><comment /></metabolite><metabolite><id>1970</id><name>L-Tyrosine</name><specimen>plasma</specimen><value>increased</value><min>19.00</min><max>119.00</max><unit>&#956;mol/l</unit><age>Childhood</age><method>HPLC</method><comment /></metabolite><metabolite><id>1971</id><name>L-Tyrosine</name><specimen>plasma</specimen><value>increased</value><min>35.00</min><max>107.00</max><unit>&#956;mol/l</unit><age>Adolescence</age><method>HPLC</method><comment /></metabolite><metabolite><id>68</id><name>4-Hydroxyphenylacetic acid</name><specimen>urine</specimen><value>increased</value><min>6.00</min><max>28.00</max><unit>mmol/mol creatinine</unit><age>childhood</age><method /><comment /></metabolite><metabolite><id>1363</id><name>4-Hydroxyphenylacetic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>59.00</max><unit>mmol/mol creatinine</unit><age>Adolescence</age><method>GCMS</method><comment /></metabolite><metabolite><id>1362</id><name>4-Hydroxyphenylacetic acid</name><specimen>urine</specimen><value>increased</value><min>3.00</min><max>240.00</max><unit>mmol/mol creatinine</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>675</id><name>4-Hydroxyphenyllactic acid</name><specimen>urine</specimen><value>increased</value><min>3.00</min><max>5.00</max><unit>mmol/mol creatinine</unit><age>infancy</age><method /><comment /></metabolite><metabolite><id>677</id><name>4-Hydroxyphenyllactic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>9.00</max><unit>mmol/mol creatinine</unit><age>childhood 6-12y</age><method /><comment /></metabolite><metabolite><id>678</id><name>4-Hydroxyphenyllactic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>7.00</max><unit>mmol/mol creatinine</unit><age>adolescence</age><method /><comment /></metabolite><metabolite><id>674</id><name>4-Hydroxyphenyllactic acid</name><specimen>urine</specimen><value>increased</value><min>0.10</min><max>11.50</max><unit>mmol/mol creatinine</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>676</id><name>4-Hydroxyphenyllactic acid</name><specimen>urine</specimen><value>increased</value><min>0.30</min><max>5.80</max><unit>mmol/mol creatinine</unit><age>child</age><method /><comment /></metabolite><metabolite><id>680</id><name>4-Hydroxyphenylpyruvic acid</name><specimen>urine</specimen><value>increased</value><min>5.00</min><max>5.00</max><unit>mmol/mol creatinine</unit><age>Infancy</age><method /><comment /></metabolite><metabolite><id>682</id><name>4-Hydroxyphenylpyruvic acid</name><specimen>urine</specimen><value>increased</value><min>1.00</min><max>3.00</max><unit>mmol/mol creatinine</unit><age>childhood 6-12y</age><method /><comment /></metabolite><metabolite><id>683</id><name>4-Hydroxyphenylpyruvic acid</name><specimen>urine</specimen><value>increased</value><min>1.00</min><max>4.00</max><unit>mmol/mol creatinine</unit><age>Adolescence</age><method /><comment /></metabolite><metabolite><id>66</id><name>4-Hydroxyphenylpyruvic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>2.00</max><unit>mmol/mol creatinine</unit><age>Childhood</age><method /><comment /></metabolite><metabolite><id>679</id><name>4-Hydroxyphenylpyruvic acid</name><specimen>urine</specimen><value>increased</value><min>0.10</min><max>21.30</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method /><comment /></metabolite><metabolite><id>1924</id><name>L-Tyrosine</name><specimen>urine</specimen><value>increased</value><min>2.00</min><max>23.00</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>1763</id><name>L-Tyrosine</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>43.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment>?</comment></metabolite><metabolite><id>155</id><name>L-Tyrosine</name><specimen>urine</specimen><value>increased</value><min>6.00</min><max>55.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>870</id><name>L-Tyrosine</name><specimen>urine</specimen><value>increased</value><min>9.00</min><max>48.00</max><unit>mmol/mol creatinine</unit><age>Childhood</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>1553</id><name>L-Tyrosine</name><specimen>urine</specimen><value>increased</value><min>6.00</min><max>26.00</max><unit>mmol/mol creatinine</unit><age>Adolescence</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>1517</id><name>L-Tyrosine</name><specimen>urine</specimen><value>increased</value><min>11.00</min><max>54.00</max><unit>mmol/mol creatinine</unit><age>Infancy</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>53</id><name>L-Tyrosine</name><specimen>plasma</specimen><value>increased</value><min>38.00</min><max>147.00</max><unit>&#956;mol/l</unit><age>Neonatal</age><method>HPLC</method><comment /></metabolite><metabolite><id>1298</id><name>L-Tyrosine</name><specimen>blood</specimen><value>increased</value><min>29.06</min><max>178.41</max><unit>&#181;mol/l</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>1299</id><name>L-Tyrosine</name><specimen>plasma</specimen><value>increased</value><min>14.00</min><max>115.00</max><unit>&#956;mol/l</unit><age>Childhood</age><method>HPLC</method><comment /></metabolite></Metabolites><Literatures><literature><id>6653</id><title>A Case of Tyrosinemia Type III with Status Epilepticus and Mental Retardation</title><author>Najafi R,</author><journal>Adv Biomed Res</journal><year>2018</year><book /><volume>7</volume><number>0</number><pages>7</pages><co_aut>Mostofizadeh N, Hashemipour M</co_aut></literature><literature><id>5173</id><title>Remaining Challenges in the Treatment of Tyrosinemia from the Clinicians Viewpoint</title><author>Mitchell GA,</author><journal>Adv Exp Med Biol</journal><year>2017</year><book /><volume>959</volume><number>0</number><pages>205-213</pages><co_aut>Yang H</co_aut></literature><literature><id>3237</id><title>Tyrosinemia Type III detected via neonatal screening: management and outcome</title><author>Heylen E,</author><journal>Mol Genet Metab</journal><year>2012</year><book /><volume>107</volume><number>3</number><pages>605-607</pages><co_aut>et al.</co_aut></literature><literature><id>3238</id><title>Increased nitric oxide release by neutrophils of a patient with tyrosinemia type III</title><author>DEufemia P,</author><journal>Biomed Pharmacother</journal><year>2009</year><book /><volume>63</volume><number>5</number><pages>359-361</pages><co_aut>et al.</co_aut></literature><literature><id>3244</id><title>Manifestation of hawkinsinuria in a patient compound heterozygous for hawkinsinuria and tyrosinemia III</title><author>Item CB,</author><journal>Mol Genet Metab</journal><year>2007</year><book /><volume>91</volume><number>4</number><pages>379-383</pages><co_aut>et al.</co_aut></literature><literature><id>1487</id><title>Expression and post-translational modification of human 4-hydroxy-phenylpyruvate dioxygenase</title><author>Aarenstrup L</author><journal>Cell Biol Int</journal><year>2002</year><book /><volume>26</volume><number>7</number><pages>615-625</pages><co_aut>et al.</co_aut></literature><literature><id>1488</id><title>Outcome of tyrosinaemia type III</title><author>Ellaway CJ</author><journal>J Inherit Metab Dis</journal><year>2001</year><book /><volume>24</volume><number>8</number><pages>824-832</pages><co_aut>et al.</co_aut></literature><literature><id>5172</id><title>Tyrosinemia: a review.</title><author>Russo PA,</author><journal>Pediatr Dev Pathol</journal><year>2001</year><book /><volume>4</volume><number>3</number><pages>212-221</pages><co_aut>Mitchell GA, Tanguay RM</co_aut></literature><literature><id>1309</id><title>Mutations in the 4-hydroxyphenylpyruvic acid dioxygenase gene are responsible for tyrosinemia type III and hawkinsinuria</title><author>Tomoeda K</author><journal>Mol Genet Metab</journal><year>2000</year><book /><volume>71</volume><number>3</number><pages>506-510</pages><co_aut>et al.</co_aut></literature><literature><id>1493</id><title>Mutations in the 4-hydroxyphenylpyruvate dioxygenase gene (HPD) in patients with tyrosinemia type III</title><author>Ruetschi U</author><journal>Hum Genet</journal><year>2000</year><book /><volume>106</volume><number>6</number><pages>654-662</pages><co_aut>et al.</co_aut></literature><literature><id>1063</id><title>Tyrosinemia type III: diagnosis and ten-year follow-up</title><author>Cerone R</author><journal>Acta Paediatr</journal><year>1997</year><book /><volume>86</volume><number>9</number><pages>1013-1015</pages><co_aut>Holme E, Schiaffino MC, Caruso U, Maritano L, Romano C</co_aut></literature><literature><id>121</id><title>Hypertyrosinemia</title><author>Mitchell GA</author><journal>The metabolic and molecular bases of inherited disease, 7/e; Editors: C.R.Scriver, A.L.Beaudet, W.S.Sly, D.Valle; McGraw-Hill Inc.</journal><year>1995</year><book /><volume>1</volume><number>0</number><pages>1077-1106</pages><co_aut>et al.</co_aut></literature><literature><id>815</id><title>Chronic tyrosinemia associated with 4-hydroxyphenylpyruvate dioxygenase deficiency with acute intermittent ataxia and without vi</title><author>Giardini O</author><journal>Pediatr Res</journal><year>1983</year><book /><volume>17</volume><number>0</number><pages>25-29</pages><co_aut>et al.</co_aut></literature><literature><id>816</id><title>Four-hydroxyphenylpyruvic acid oxidase deficiency with normal fumarylacetoacetase: A new variant form of hereditary hypertyrosin</title><author>Endo F</author><journal>Pediatr Res</journal><year>1983</year><book /><volume>17</volume><number>0</number><pages>92-96</pages><co_aut>et al.</co_aut></literature></Literatures></Disease>